Comparison Overview

AUROBINDO PHARMA LTD

VS

Johnson & Johnson Innovative Medicine

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-09
View Profile
Between 750 and 799
https://www.aurobindo.com/

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Johnson & Johnson Innovative Medicine

None
Last Update: 2025-12-09
Between 750 and 799
https://innovativemedicine.jnj.com/

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 17,292
Subsidiaries: 10
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AUROBINDO PHARMA LTD
100%
Compliance Rate
0/4 Standards Verified
Johnson & Johnson Innovative Medicine
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2025.

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Incident History — Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

https://images.rankiteo.com/companyimages/jnjinnovativemedicine.jpeg
Johnson & Johnson Innovative Medicine
Incidents

No Incident

FAQ

Johnson & Johnson Innovative Medicine company demonstrates a stronger AI Cybersecurity Score compared to AUROBINDO PHARMA LTD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Johnson & Johnson Innovative Medicine company has disclosed a higher number of cyber incidents compared to AUROBINDO PHARMA LTD company.

In the current year, Johnson & Johnson Innovative Medicine company and AUROBINDO PHARMA LTD company have not reported any cyber incidents.

Neither Johnson & Johnson Innovative Medicine company nor AUROBINDO PHARMA LTD company has reported experiencing a ransomware attack publicly.

Neither Johnson & Johnson Innovative Medicine company nor AUROBINDO PHARMA LTD company has reported experiencing a data breach publicly.

Neither Johnson & Johnson Innovative Medicine company nor AUROBINDO PHARMA LTD company has reported experiencing targeted cyberattacks publicly.

Neither AUROBINDO PHARMA LTD company nor Johnson & Johnson Innovative Medicine company has reported experiencing or disclosing vulnerabilities publicly.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds any compliance certifications.

Neither company holds any compliance certifications.

Johnson & Johnson Innovative Medicine company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

Johnson & Johnson Innovative Medicine company employs more people globally than AUROBINDO PHARMA LTD company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 1 certification.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds SOC 2 Type 2 certification.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds ISO 27001 certification.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds PCI DSS certification.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds HIPAA certification.

Neither AUROBINDO PHARMA LTD nor Johnson & Johnson Innovative Medicine holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.

Published
Date
2025-12-13
Updated
Date
2025-12-13
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References